INTRODUCTION
============

The toll-like receptor (TLR) 6 has a role in the innate immunity, as receptor for pathogenic molecules ([@b11-jer-9-6-526-8]) and endogeneous damage-associated molecules ([@b20-jer-9-6-526-8]). TLR6 is known as a receptor for mycobacterial infection ([@b25-jer-9-6-526-8]), and associated with recognization of bacterial lipopeptides and lipoteichoic acid ([@b9-jer-9-6-526-8]).

TLRs have receptor function for specific molecules ([@b11-jer-9-6-526-8]; [@b20-jer-9-6-526-8]), and the overall expression of TLRs may activate the subsequent inflammatory response cascades ([@b11-jer-9-6-526-8]). TLRs that expressed on the cell membrane need to be dimerized to transduce signals into cytoplasmic pathways. Among them, TLR1 is the most expressed and may be dimerized with any other TLRs to transduce the recognized signals by other TLRs. For the TLR6, TLR2 is the major TLR dimers with it ([@b9-jer-9-6-526-8]).

Interestingly, there is a TLR10/TLR1/TLR6 locus on chromosome 4 ([@b15-jer-9-6-526-8]), and the locus forms a complex to genetically affect, or to be associated with, other immune response related genes. And it implies that TLR6 may have close genetic relationship to TLR1, the most expressed TLR which may affect the signal transduction of many TLRs. There was a report that the genetic variation in the TLR10/TLR1/TLR6 complex may determine the TLR1 and TLR2 mediated responses in the individuals ([@b15-jer-9-6-526-8]). And TLR1 and TLR2 is associated with activation of inflammatory responses in central nervous system, such as microglial cells, glial progenitors, neurons, astrocytes, as well as peripheral blood monocytes ([@b3-jer-9-6-526-8]). In the Lyme disease, TLR1 and 2 may affect the human leukocyte antigen (HLA)-class II expressions and therefore, differential symptoms, such as whether central nervous system manifestation develops in individuals, may be determined. Moreover, TNF-alpha mediated inflammation may contribute to the cerebral aneurysms, which is another cerebral artery disease and related with severe inflammatory responses, and TLR-mediated innate immunity was related with higher TNF-alpha expression ([@b10-jer-9-6-526-8]). Such evidences suggest that TLRs may affect many vascular diseases, such as stroke, however TLR6 was mostly studied in the pulmonary diseases, such as bronchiolitis ([@b17-jer-9-6-526-8]), Legionnaires' disease ([@b16-jer-9-6-526-8]), and bronchial effect of ureaplasma ([@b24-jer-9-6-526-8]), but no previous study was reported whether the TLR6 polymorphisms may affect the development or clinical features of stroke.

Therefore, we investigated associations between the single nucleotide polymorphism (SNP) of TLR6 and development or clinical features of ischemic stroke.

MATERIALS AND METHODS
=====================

Study subjects
--------------

Stroke patients were recruited from Kyung Hee Medical Center. [Table 1](#t1-jer-9-6-526-8){ref-type="table"} shows the clinical characteristics study participants. The controls were 278 aged male and female (148 male and 130 female, mean age 63.6 yr) without any severe diseases. And the stroke patients were 120 aged male and female (67 male and 53 female, mean age 65.8 yr), and their clinical characteristics such as National Institutes of Health Stroke Scale (NIHSS) and modified barthel index (MBI) were analyzed. Ethical approval of this study was obtained from the ethics review committee of Medical Research Institute, School of Medicine, Kyung Hee University, Seoul, Korea.

SNP selection and genotyping
----------------------------

We selected four SNPs in TLR6: rs1039559 (intron), rs3821985 (Thr361Thr), rs3775073 (Lys421Lys), and rs5743818 (Ala644A-la). They were searched from the SNP database in NCBI (<http://www.ncbi.nlm.nih.gov/SNP>), and reviewed to select the region in exons and near exons. Peripheral blood of all patients were sampled in EDTA blood tube, stored in −20°C freezer before the extraction of genomic DNA. Genomic DNA was extracted with QIAamp^®^ DNA extraction kit (QIAGEN, Valencia, CA, USA). Polymerase chain reactions (PCRs) of the SNPs were performed using the following primers in the [Table 2](#t2-jer-9-6-526-8){ref-type="table"} to amplify target sequences including the SNPs. The primers used in this study were in a previous study of TLRs ([@b12-jer-9-6-526-8]). Direct sequencing, sequence sorting, and analyzing were done with ABI PRISM 3730XL analyzer (PE Applied Biosystems, Foster City, CA, USA) and with SeqManII software (DNASTAR, Madison, WI, USA).

Statistical analysis
--------------------

SNPStats (<http://bioinfo.iconcologia.net/index.php?module=Snpstats>) and SPSS 20.0 (SPSS Inc., Chicago, IL, USA) were used to obtain odds ratios (ORs), 95% confidence intervals (CIs), and *P* values. Multiple logistic regression models were applied in the analysis of genotypes. Each component of the model was: codominant1 (major allele homozygotes vs heterozygotes), codominant2 (major allele homozygotes vs minor allele homozygotes), dominant (major allele homozygotes vs heterozygotes+minor allele homozygotes), recessive (major allele homozygotes+heterozygotes vs. minor allele homozygotes), and log-additive (major allele homozygotes vs. heterozygotes vs. minor allele homozygotes) ([@b12-jer-9-6-526-8]). Age and gender were included as covariates and adjusted to obtain statistical significance. The linkage disequilibrium (LD) block and haplotypes between pairs of SNPs were tested with Haploview 4.2 software (Daly Lab, Cambridge, MA, USA). In the statistical analysis, *P*\<0.05 was considered significant. Hardy-Weinberg equilibrium of each SNP was tested in SNPstats.

RESULTS
=======

The frequencies of genotype and allele of TLR6 in control and patients with ischemic stroke were displayed in the [Table 3](#t3-jer-9-6-526-8){ref-type="table"}, however, there was no significantly associated with development of ischemic stroke (*P*\>0.05). All of the four tested SNPs were in Hardy-Weinberg equilibrium (data not shown).

The genotype and allele frequencies of SNPs of TLR6 gene in ischemic stroke patients with NIHSS score (\<6) and ICH patients with NIHSS score (≥6) show in the [Table 4](#t4-jer-9-6-526-8){ref-type="table"}. For the two of synonymous SNPs rs3821985 (Thr361Thr) and rs3775073 (Lys421-Lys), the genotype distributions were associated with NIHSS (rs-3821985 and rs3775073, OR=0.40, 95% CI=0.18--0.90, *P*= 0.026 in codominant1, OR=0.40, 95% CI=0.19--0.88, *P*=0.02 in dominant, and OR=0.54, 95% CI=0.30--0.99, *P*=0.043 in log-additive).

The allele frequencies of rs3821985 and rs3775073 were also associated with NIHSS (OR=0.57, 95% CI=0.32--0.99, *P*=0.048), in both SNPs. However, an intronic SNP rs1039559 and a synonymous SNP rs5743818 (Ala644Ala) was not associated with NIHSS in this study.

The genotype and allele frequencies of SNPs of TLR6 gene in ischemic stroke patients with MBI score (\<60) and ischemic stroke patients with MBI score (≥60) were shown in the [Table 5](#t5-jer-9-6-526-8){ref-type="table"}. An intronic SNP rs1039559 was associated with MBI score of stroke patients (OR=0.30, 95% CI=0.10--0.90, *P*=0.032 in codominant, OR=0.27, 95% CI=0.09--0.81, *P*=0.014 in dominant, and OR=0.28, 95% CI=0.10--0.80, *P*=0.0096 in log-additive). And the two of synonymous SNPs rs3821985 (Thr361Thr) and rs3775073 (Lys421Lys) also were associated with MBI in codominant1 (OR=3.36, 95% CI=1.07--10.60, *P*=0.038) model.

There was a LD block between only three (rs1039559, rs3821985, and rs3775073) of the four tested SNPs ([Fig. 1](#f1-jer-9-6-526-8){ref-type="fig"}), and the LD block was strong between rs3821985 and rs3775073 (D'=1.0, r-squared=1.0). Therefore, haplotype analysis was performed; however, no haplotype was significantly associated with the development of ischemic stroke (*P*\>0.05).

DISCUSSION
==========

TLR6 is located on the chromosome 4, forming a locus of TLR10/TLR1/TLR6 complex. The locus is associated with many relatively common diseases, such as papillary thyroid carcinoma ([@b12-jer-9-6-526-8]), sarcoidosis ([@b23-jer-9-6-526-8]), Crohn's disease ([@b1-jer-9-6-526-8]), and various cancer risks ([@b13-jer-9-6-526-8]).

Function of TLR6 may be disturbed by genetic defects ([@b6-jer-9-6-526-8]). Changes in the genome of individual may contribute to the altered innate immune responses, and auch influence may involve inflammatory cytokines and chemokines, such as IL-1β, IL-6, IL-8, IL-12, and TNF-α ([@b6-jer-9-6-526-8]).

Inflammatory mediators are important in stroke, because vascular inflammations may lead to the development of stroke ([@b4-jer-9-6-526-8]), and moreover, responses of such genes are related to the pathologic process after the hemorrhage occurs ([@b2-jer-9-6-526-8]; [@b19-jer-9-6-526-8]; [@b26-jer-9-6-526-8]). NLRP3 inflammasome is a major component of the innate immune system, which affects the neutrophil function and edematous tissue responses ([@b14-jer-9-6-526-8]). The action of inflammasome involves the caspase-1, IL-1b, moreover, it is associated with activation of TLRs ([@b5-jer-9-6-526-8]). Tissue hypoxia caused by ischemic changes in stroke ([@b19-jer-9-6-526-8]) may lead to ischemia-induced inflammatory responses, which was well-investigated in cardiovascular diseases ([@b7-jer-9-6-526-8]) and cerebrovascular diseases ([@b22-jer-9-6-526-8]). In cerebrovascular disease models, microglial activation is an important phenomenon in ischemic inflammatory responses, and TLR6 was reported to be associated with microglial responses. TLR6 with TLR4 forms a dimer and it may promote inflammations by CD36 ligand, which is also related to oxidative injury and hemorrhagic disorders ([@b18-jer-9-6-526-8]).

In our result, two exonic SNPs rs3821985 and rs3775073 were associated with the clinical features (NIHSS and MBI) of stroke, and an intronic SNP rs1039559 was associated with MBI. Interestingly, only intronic SNP rs1039559 was previously reported to be associated with higher total immunoglobulin (Ig) E levels, especially in the children aged 1--2 yr ([@b21-jer-9-6-526-8]). There have been some previous studies of Ser249Pro, a famous SNP in TLR6, however, reported only association with asthmatic disorders ([@b8-jer-9-6-526-8]). Therefore, it may be the first study to report the association between TLR6 and stroke.

In conclusion, we suggest that SNPs of TLR6 (rs1039559, rs-3821985, and rs3775073) may affect the disease characteristics of ischemic stroke, such as NIHSS and MBI. Additionally, MBI is a score related to the functional assessment of rehabilitation, our result may contribute to the genetic study of rehabilitation fields. Our study has some limitations, such as only small population of Korean were analyzed. Therefore, more subjects will be needed to confirm our results in further study.
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###### 

Clinical characteristics in IS and control subjects

                        IS           Control
  --------------------- ------------ -----------
  Total number          120          278
  Male/female (n)       67/53        148/130
  Age (mean age ± SD)   65.8± 12.1   63.6± 9.2
  NIHSS (score)                      
    \< 6                56           
    ≥ 6                 56           
  MBI (score)                        
    \< 60               70           
    ≥ 60                25           

Stroke patients with inappropriate clinical data were excluded. IS, ischemic stroke; SD, standard deviation; NIHSS, National Institutes of Health Stroke Survey; MBI, Modified Barthel Index.

###### 

Primer sequences for each SNP

  SNPs        Sense (5′-3′)            Anti-sense (5′-3′)       Size (bp)
  ----------- ------------------------ ------------------------ -----------
  rs1039559   GTGGTTGTGTGTTTTGACCTGT   TGTTGGATCACTTTCTCAATGC   452
  rs3821985   TTGAAAGCATTCGTGAAGAAGA   TGATCCTGGGAGGTAAACATCT   492
  rs3775073   TACCTTGATCCTGGGAGGTAAA   TTGAAAGCATTCGTGAAGAAGA   497
  rs5743818   AGCCCACTAAAGGACTTTCACA   GGGAGACAAAACAAAGATGGAC   405

SNP, single nucleotide polymorphism.

###### 

Frequencies of genotype and allele of TLR6 in control and patients with IS

  SNP         Genotype/allele   Control      IS           Models         OR (95% CI)         *P*
  ----------- ----------------- ------------ ------------ -------------- ------------------- ---------
  rs1039559   T/T               141 (50.7)   64 (53.3)    Codominant1    0.91 (0.58--1.43)   0.69
  Intron      T/C               118 (42.5)   49 (40.8)    Codominant2    0.78 (0.31--1.97)   0.60
              C/C               19 (6.8)     7 (5.8)      Dominant       0.90 (0.58--1.38)   0.61
                                                          Recessive      0.82 (0.33--2.01)   0.65
                                                          Log-additive   0.90 (0.63--1.28)   0.56
              T                 400 (71.9)   177 (73.8)                  1                   
              C                 156 (28.1)   63 (26.2)                   0.91 (0.65--1.29)   0.60
  rs3821985   C/C               146 (52.5)   54 (45.0)    Codominant1    1.38 (0.88--2.18)   0.16
  Thr361Thr   C/G               105 (37.8)   54 (45.0)    Codominant2    1.20 (0.56--2.55)   0.64
              G/G               27 (9.7)     12 (10.0)    Dominant       1.35 (0.87--2.07)   0.18
                                                          Recessive      1.03 (0.50--2.13)   0.93
                                                          Log-additive   1.19 (0.86--1.64)   0.29
              C                 397 (71.4)   162 (67.5)                  1                   
              G                 159 (28.6)   78 (32.5)                   1.20 (0.87--1.67)   0.27
  rs3775073   A/A               146 (52.5)   54 (45.0)    Codominant1    1.38 (0.88--2.18)   0.16
  Lys421Lys   A/G               105 (37.8)   54 (45.0)    Codominant2    1.20 (0.56--2.55)   0.64
              G/G               27 (9.7)     12 (10.0)    Dominant       1.35 (0.87--2.07)   0.18
                                                          Recessive      1.03 (0.50--2.13)   0.93
                                                          Log-additive   1.19 (0.86--1.64)   0.29
              A                 397          162                         1                   
              G                 159          78                          1.20 (0.87--1.67)   0.27
  rs5743818   T/T               265 (95.3)   117 (97.5)   Codominant1    0.57 (0.16--2.06)   0.37
  Ala644Ala   T/G               13 (4.7)     3 (2.5)                                         
              T                 543 (97.7)   237 (98.8)                  1                   
              G                 13 (2.3)     3 (1.2)                     0.53 (0.15--1.87)   0.42^c^

The *P* values were calculated from logistic regression analysis adjusting sex and age. The *P*^c^ was calculated using Fisher's exact test. IS, ischemic stroke; SNP, singe nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Genotype and allele frequencies of SNPs of TLR6 gene in IS patients with NIHSS score (\< 6) and ICH patients with NIHSS score (≥ 6)

  SNP         Genotype/allele   NHISS (\< 6)   NHISS (≥ 6)   Models         OR (95% CI)           *P*
  ----------- ----------------- -------------- ------------- -------------- --------------------- -----------
  rs1039559   T/T               33 (58.9)      25 (44.6)     Codominant1    1.91 (0.87--4.18)     0.11
  Intron      T/C               19 (33.9)      28 (50.0)     Codominant2    0.94 (0.19--4.67)     0.94
              C/C               4 (7.1)        3 (5.4)       Dominant       1.74 (0.82--3.71)     0.15
                                                             Recessive      0.70 (0.15--3.32)     0.65
                                                             Log-additive   1.37 (0.74--2.55)     0.31
              T                 85 (75.9)      78 (69.6)                    1                     
              C                 27 (24.1)      34 (30.4)                    1.37 (0.76--2.48)     0.29
  rs3821985   C/C               19 (33.9)      31 (55.4)     Codominant1    0.40 (0.18--0.90)     **0.026**
  Thr361Thr   C/G               30 (53.6)      20 (35.7)     Codominant2    0.43 (0.11--1.64)     0.22
              G/G               7 (12.5)       5 (8.9)       Dominant       0.40 (0.19----0.88)   **0.02**
                                                             Recessive      0.71 (0.20--2.47)     0.58
                                                             Log-additive   0.54 (0.30--0.99)     **0.043**
              C                 68 (60.7)      82 (73.2)                    1                     
              G                 44 (39.3)      30 (26.8)                    0.57 (0.32--0.99)     **0.048**
  rs3775073   A/A               19 (33.9)      31 (55.4)     Codominant1    0.40 (0.18--0.90)     **0.026**
  Lys421Lys   A/G               30 (53.6)      20 (35.7)     Codominant2    0.43 (0.11--1.64)     0.22
              G/G               7 (12.5)       5 (8.9)       Dominant       0.40 (0.19--0.88)     **0.02**
                                                             Recessive      0.71 (0.20--2.47)     0.58
                                                             Log-additive   0.54 (0.30--0.99)     **0.043**
              A                 68 (60.7)      82 (73.2)                    1                     
              G                 44 (39.3)      30 (26.8)                    0.57 (0.32--0.99)     **0.048**
  rs5743818   T/T               53 (94.6)      56 (100.0)    Codominant1    0.00 (0.00-NA)        NA
  Ala644Ala   T/G               3 (5.4)        0 (0.0)                                            
              T                 109 (97.3)     112 (100.0)                                        
              G                 3 (2.7)        0 (0.0)                                            0.25^c^

The *P* values were calculated from logistic regression analysis adjusting sex and age. The *P*^c^ was calculated using Fisher's exact test. Bold numbers indicate significant associations. IS, ischemic stroke; SNP, singe nucleotide polymorphism; NIHSS, National Institutes of Health Stroke Survey; OR, odds ratio; CI, confidence interval; NA, not applicable.

###### 

Genotype and allele frequencies of SNPs of TLR6 gene in IS patients with MBI score (\< 60) and IS patients with MBI score (≥ 60)

  SNP         Genotype/allele   MBI (\< 60)   MBI (≥ 60)   Models         OR (95% CI)          *P*
  ----------- ----------------- ------------- ------------ -------------- -------------------- ------------
  rs1039559   T/T               33 (47.1)     19 (76.0)    Codominant1    0.30 (0.10--0.90)    **0.032**
  Intron      T/C               33 (47.1)     6 (24.0)     Codominant2    0.00 (0.00-NA)       NA
              C/C               4 (5.7)       0 (0.0)      Dominant       0.27 (0.09--0.81)    **0.014**
                                                           Recessive      0.00 (0.00-NA)       NA
                                                           Log-additive   0.28 (0.10--0.80)    **0.0096**
              T                 99 (70.7)     44 (88.0)                   1                    
              C                 41 (29.3)     6 (12.0)                    0.33 (0.13--0.83)    0.019
  rs3821985   C/C               32 (45.7)     7 (28.0)     Codominant1    3.36 (1.07--10.60)   **0.038**
  Thr361Thr   C/G               30 (42.9)     16 (64.0)    Codominant2    0.57 (0.09--3.54)    0.55
              G/G               8 (11.4)      2 (8.0)      Dominant       2.27 (0.79--6.52)    0.12
                                                           Recessive      0.31 (0.06--1.68)    0.14
                                                           Log-additive   1.16 (0.57--2.37)    0.68
              C                 94 (67.1)     30 (60.0)                   1                    
              G                 46 (32.9)     20 (40.0)                   1.36 (0.70--2.65)    0.36
  rs3775073   A/A               32 (45.7)     7 (28.0)     Codominant1    3.36 (1.07--10.60)   **0.038**
  Lys421Lys   A/G               30 (42.9)     16 (64.0)    Codominant2    0.57 (0.09--3.54)    0.55
              G/G               8 (11.4)      2 (8.0)      Dominant       2.27 (0.79--6.52)    0.12
                                                           Recessive      0.31 (0.06--1.68)    0.14
                                                           Log-additive   1.16 (0.57--2.37)    0.68
              A                 94 (67.1)     30 (60.0)                   1                    
              G                 46 (32.9)     20 (40.0)                   1.36 (0.70--2.65)    0.36
  rs5743818   T/T               67 (95.7)     25 (100.0)   Codominant1    0.00 (0.00-NA)       NA
  Ala644Ala   T/G               3 (4.3)       0 (0.0)                                          
              T                 137 (97.9)    50 (100.0)                                       
              G                 3 (2.1)       0 (0.0)                                          0.57^c^

The *P* values were calculated from logistic regression analysis. The *P*^c^ was calculated using Fisher's exact test. Bold numbers indicate significant associations. IS, ischemic stroke; SNP, singe nucleotide polymorphism; MBI, Modified Barthel Index; OR, odds ratio; CI, confidence interval; NA, not applicable.
